Compare Adaptive Biotechnologies Corp (ADPT) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs DENTSPLY SIRONA Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.57 (market cap $4.04B), while DENTSPLY SIRONA Inc trades at $11.58 (market cap $2.31B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | XRAY | |
|---|---|---|
Market Cap | $4.04B | $2.31B |
Sector | Health | Health |
52-Week High | $25.45 | $14.68 |
52-Week Low | $12.30 | $9.64 |
Enterprise Value | $4.10B | $4.39B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
DENTSPLY SIRONA (XRAY) trades at $11.66, down 3.8% on the day, with a bearish technical outlook and mixed fundamentals. The stock faces headwinds from declining revenue and negative profitability, though Q2 2026 earnings beat expectations. Recent news highlights institutional stake increases and ongoing turnaround efforts amid weak dental market conditions.
The outlook remains challenging with persistent net losses and high debt, but cost controls and strategic partnerships offer potential stabilization. Risks include competitive pressures and macroeconomic softness, while analyst consensus is Hold with a $11.50 price target, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
